Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the ...
Proceeds to support the clinical development of lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth (CMT) disease, with Phase I trials starting imminently Pipeline of next ...
Pharmaceutical Technology on MSN9d
Augustine secures $85m to advance Charcot-Marie-Tooth candidateAugustine Therapeutics has raised €78m ($85m) in funding to support the development of its lead candidate as it enters a ...
Augustine Therapeutics has raised €78 million ($85 million) in first-round funding for a pipeline headed by a candidate for ...
Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investors Proceeds to support the clinical development of lead candidate AGT-100216 for the treatment of ...
By Karen Roman Private equity company Jeito Capital said it is co-leading an oversubscribed €77.7 million (USD 84.8 million) ...
Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investors Proceeds to support the clinical development of lead candidate AGT-100216 for the treatment of ...
Augustine Therapeutics is a biotechnology company focused on the treatment of neuromuscular, neurodegenerative and cardio-metabolic diseases through its next-generation approach to selectively ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback